2 assets in Cervix Melanoma

Therapeutic assets addressing Cervix Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Cervix Melanoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Cervix Melanoma	National Cancer Institute (NCI)	P2	CCC (53)